IONIS PHARMACEUTICALS INC
For the period ended Sep 30, 2026. Filed Nov 9, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Nov 9, 2026
IONS$31.00-21.4%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Balance Sheets
(in thousands, except share data)
| September 30, | December 31, | |
|---|---|---|
| 2026 | 2025 | |
| (unaudited) | ||
| ASSETS | ||
| Current assets: | ||
| Cash and cash equivalents | $296,303 | $372,260 |
| Short-term investments | 1,587,604 | 2,305,176 |
| Contracts receivable | 88,340 | 66,059 |
| Inventories | 28,578 | 10,048 |
| Other current assets | 360,676 | 237,092 |
| Total current assets | 2,361,501 | 2,990,635 |
| Property, plant and equipment, net | 162,059 | 123,048 |
| Right-of-use assets | 228,035 | 238,549 |
| Deposits and other assets | 160,995 | 171,604 |
| Total assets | $2,912,590 | $3,523,836 |
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||
| Current liabilities: | ||
| Accounts payable | $27,113 | $28,082 |
| Accrued compensation | 61,379 | 116,236 |
| Accrued liabilities | 116,177 | 106,089 |
| Income taxes payable | 109 | 2,713 |
| 0 percent convertible senior notes due April 2026, net | - | 431,948 |
| Liability related to sale of future royalties, net | 138,188 | 11,689 |
| Current portion of deferred contract revenue | 70,203 | 73,761 |
| Other current liabilities | 22,123 | 11,049 |
| Total current liabilities | 435,292 | 781,567 |
| Long-term deferred contract revenue | 48,755 | 92,001 |
| 0 percent convertible senior notes due 2030, net | 754,289 | 751,495 |
| 1.75 percent convertible senior notes due 2028, net | 569,974 | 567,830 |
| Liability related to sale of future royalties, net | 427,840 | 551,353 |
| Long-term lease liabilities | 262,477 | 262,383 |
| Long-term obligations | 20,323 | 28,118 |
| Total liabilities | 2,518,950 | 3,034,747 |
| Stockholders’ equity: | ||
| Common stock, $0.001 par value; 300,000,000 shares authorized, 166,410,425 and 163,304,875 shares issued and outstanding at September 30, 2026 and December 31, 2025, respectively | 166 | 163 |
| Additional paid-in capital | 3,381,632 | 3,145,402 |
| Accumulated other comprehensive loss | (39,818) | (25,281) |
| Accumulated deficit | (2,948,340) | (2,631,195) |
| Total stockholders' equity | 393,640 | 489,089 |
| Total liabilities and stockholders’ equity | $2,912,590 | $3,523,836 |
Index
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.